Carl Johan Kördel

Part of Kancera AB, iNovacia AB is a Swedish company that provides pre-clinical research services. The company is based in Stockholm, Sweden. The company was founded by Martin Norin, Carl Johan Kördel, Philippe Verwaerde. Thomas Olin has been the CEO of the company since 2006. iNovacia was acquired by Kancera AB on February 17, 2011 for $0.05 million.

Ipsen Bioinnovation Ltd. Engages in the research and development of pharmaceutical products. The company was founded in 2005 and is headquartered in Abingdon, the United Kingdom.

Lundbeckfonden Ventures (Lundbeckfonden Ventures) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2009 and is headquartered in Copenhagen, Denmark.

Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA.

Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom.

Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France.

River Vision Development Corp. develops novel protein therapies. The firm provides therapy for the treatment of graves orbitopathy which is a condition in which an autoimmune response is mounted against tissues behind the eye, causing inflammation, tissue proliferation and excess production of extracellular matrix. The company was founded in 2011 and is headquartered in New York, NY.

Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA.

Ziarco Pharma Ltd. provides therapeutics targeting inflammatory and allergic diseases. It focuses on chronic inflammatory skin diseases, atopic dermatitis, and Psoriasis. The company was founded by Michael Yeadon, Wai Leung Liu, Lynn Worth Purkins and Arif Kassam Shivji in 2012 and is headquartered in Sandwich, the United Kingdom.

VHsquared Ltd. develops antibody domain products. It operates as a development stage biologics company which develops a portfolio of orally delivered antibody domain products for gastro intestinal health. The company's novel antibody platform will provide a portfolio of new and innovative functional food products to target gastrointestinal infectious and immune mediated diseases. VHsquared leverages the existing research and expertise at the Sanger Institute to facilitate the development of products that function at the gastro intestinal mucosal interface harnessing recent technological developments, including analysis of the micro biota and advances in mucosal immunology. VHsquared was founded in 2010 by William Roderick Justin Richards, Janet Rosemary Robinson, James Scott Crowe, and Gordon Dougan and is headquartered in Cambridge, the United Kingdom.

BONE SUPPORT AB manufactures orthopedic supplies and equipment. Its products include cerament bone void filler, cerament G with gentamicin, cerament V with vancomycin. The company was founded by Lars Ake Alvar Lidgren in 1999 and is headquartered in Lund, Sweden.

Acacia Pharma Group Plc is a holding company, which engages in the development and commercialization of pharmaceutical product. It focuses on the new nausea and vomiting treatments for surgical and cancer patients. The company was founded by Julian Clive Gilbert, Robert William Gristwood, and Andrew Muncey in 2007 and is headquartered in Duxford, the United Kingdom.

SARomics Biostructures AB provides protein three-dimensional structure determination and structure-based drug discovery services. The firm develops premium structural biology services. It offers crystallography services, which include crystallization screen and structure determination, nuclear magnetic resonance spectroscopy services, such as ligand binding assays/fragment screening, structure determination, and verification of the structural integrity of target protein, gene-to-structure services, such as protein cloning, expression, purification, and structure determination, kinase structures and kinobits, which include pre-made complexes of kinases with small-molecule fragments to serve as a starting point in a discovery project, structure-based drug discovery services, such as hit identification, hit optimization, and lead generation, gene-to lead services, including a combination of gene-to-structure and structure-based drug discovery, and structure-activity protein optimization services. The company was founded by Björn Ulrik Walse, Sven Anders Mikael Akke, Derek W. Logan, Salam Al-Karadaghi, and Bo Svensson in 2006 and is headquartered in Lund, Sweden.

Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA.

Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden.

Curzion Pharmaceuticals, Inc. operates as a pharmaceutical firm. The company is headquartered in San Diego, CA.

Industrifonden is a Venture Capital firm, a subsidiary of Government of Sweden founded in 1979. The firm is headquartered in Stockholm.

Sound Bioventures Management AB is a venture capital firm founded in 2021 by Casper Breum, Johan Kordel and Bibhash Mukhopadhyay. The firm is headquartered in Malmo, Sweden.